LifeVantage Corporation engages in the identification, research, development, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, and skin and hair care products. More Details
No risks detected for L2T1 from our risk checks.
Flawless balance sheet with outstanding track record.
Share Price & News
How has LifeVantage's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: L2T1 is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: L2T1's weekly volatility (6%) has been stable over the past year.
7 Day Return
DE Personal Products
1 Year Return
DE Personal Products
Return vs Industry: L2T1 underperformed the German Personal Products industry which returned 1.8% over the past year.
Return vs Market: L2T1 underperformed the German Market which returned 0.6% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is LifeVantage's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is LifeVantage undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: L2T1 (€9.3) is trading below our estimate of fair value (€33.6)
Significantly Below Fair Value: L2T1 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: L2T1 is good value based on its PE Ratio (12.9x) compared to the XE Personal Products industry average (20.8x).
PE vs Market: L2T1 is good value based on its PE Ratio (12.9x) compared to the German market (23.2x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate L2T1's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: L2T1 is overvalued based on its PB Ratio (4.7x) compared to the XE Personal Products industry average (2.4x).
How is LifeVantage forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Household industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as LifeVantage has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine whether LifeVantage is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- LifeVantage competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Household industry.
How has LifeVantage performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: L2T1 has high quality earnings.
Growing Profit Margin: L2T1's current net profit margins (5.3%) are higher than last year (3.7%).
Past Earnings Growth Analysis
Earnings Trend: L2T1's earnings have grown significantly by 28.2% per year over the past 5 years.
Accelerating Growth: L2T1's earnings growth over the past year (47.2%) exceeds its 5-year average (28.2% per year).
Earnings vs Industry: L2T1 earnings growth over the past year (47.2%) exceeded the Personal Products industry 16.3%.
Return on Equity
High ROE: L2T1's Return on Equity (35.9%) is considered high.
How is LifeVantage's financial position?
Financial Position Analysis
Short Term Liabilities: L2T1's short term assets ($41.0M) exceed its short term liabilities ($22.0M).
Long Term Liabilities: L2T1's short term assets ($41.0M) exceed its long term liabilities ($14.1M).
Debt to Equity History and Analysis
Debt Level: L2T1 is debt free.
Reducing Debt: L2T1 has no debt compared to 5 years ago when its debt to equity ratio was 360%.
Debt Coverage: L2T1 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: L2T1 has no debt, therefore coverage of interest payments is not a concern.
What is LifeVantage current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate L2T1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate L2T1's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if L2T1's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if L2T1's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of L2T1's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Steve Fife (59 yo)
Mr. Steven R. Fife, also known as Steve, has been the Chief Financial Officer of Lifevantage Corporation since March 13, 2017 and also serves as its Interim President and Chief Executive Officer since Sept...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD1.07M) is above average for companies of similar size in the German market ($USD692.51K).
Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.
|Interim President||0.17yr||US$1.07m||0.60% |
|General Counsel||3.17yrs||US$678.14k||0.27% |
|Chief Sales & Marketing Officer||5.33yrs||US$734.55k||0.87% |
|Chief Operating Officer||3.67yrs||US$572.31k||0.15% |
|Vice President of Compliance||no data||no data||no data|
|Director of Communications||no data||no data||no data|
|Senior Vice President of Human Resources||5yrs||US$627.21k||no data|
|Senior Vice President of Global Field Development||4.33yrs||no data||no data|
|Senior Vice President of Research & Development||1.33yrs||no data||no data|
|Managing Director - Japan||no data||no data||no data|
Experienced Management: L2T1's management team is considered experienced (3.7 years average tenure).
|Independent Director||8.83yrs||US$142.78k||0.53% |
|Independent Director||3.75yrs||US$136.78k||0.36% |
|Independent Director||3.75yrs||US$142.78k||0.38% |
|Independent Chairman||7yrs||US$148.78k||1% |
|Independent Director||3.75yrs||US$136.78k||0.35% |
|Independent Director||1.5yrs||US$136.78k||0.060% |
Experienced Board: L2T1's board of directors are considered experienced (3.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
LifeVantage Corporation's company bio, employee growth, exchange listings and data sources
- Name: LifeVantage Corporation
- Ticker: L2T1
- Exchange: DB
- Industry: Personal Products
- Sector: Household
- Market Cap: US$158.938m
- Listing Market Cap: US$133.492m
- Shares outstanding: 14.24m
- Website: https://www.lifevantage.com
Number of Employees
- LifeVantage Corporation
- 9785 South Monroe Street
- Suite 400
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|LFVN||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Oct 2004|
|L2T1||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Oct 2004|
LifeVantage Corporation engages in the identification, research, development, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, and skin...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/26 19:30|
|End of Day Share Price||2020/11/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.